Biosimilars Drug Research Trials 
The Pharma Data
NOVEMBER 10, 2020
Innovent has established a robust pipeline of 23 valuable assets, including four launched products, four products in pivotal trials, and multiple prioritized assets such as CD47, PDL1/CD47, TIGIT, VEGF/complement protein etc. that are fast progressing clinical trials. TYVYT® is the only PD-1 inhibitor included in the NRDL.
Agency IQ
AUGUST 2, 2024
While the work on the pharma package will likely take quite some time, another deadline is coming up fast: the full transition of all clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation.
Agency IQ
JUNE 9, 2023
The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Additionally, the smaller potential customer base may provide an insufficient return on the investment into research.
Expert insights. Personalized for you.
52 
Let's personalize your content